問卷

TPIDB > Study Site

Study Site



National Taiwan University Hospital

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

篩選

List

3322Cases

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2011-06-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2010-08-01 - 2020-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2009-08-01 - 2011-03-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-08-01 - 2020-04-30

Phase III

A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease
  • Condition/Disease

    mild to moderate Alzheimer's disease patient

  • Test Drug

    Donepezil transdermal patch

Participate Sites
12Sites

Terminated12Sites

2017-08-01 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated7Sites

2017-07-01 - 2018-09-30

Phase II

A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers
  • Condition/Disease

    Influenza Virus Vaccine

  • Test Drug

    AD07030

Participate Sites
5Sites

Terminated5Sites

2015-04-15 - 2020-09-30

Phase I

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer
  • Condition/Disease

    Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Test Drug

    OBI-833 (Globo H-CRM197)/OBI-821

Participate Sites
4Sites

Recruiting4Sites

李凱靈
Taipei Medical University Hospital

Division of Hematology & Oncology

2014-07-01 - 2017-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-07-01 - 2026-07-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites